Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia

Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia

IntroductionAbout half of patients with Acute Myeloid Leukemia (AML) are not eligible for Standard Induction Chemotherapy (SIC). Hypomethylating Agents (HMAs) intravenously (IV) or subcutaneously (SC) in a clinical setting are typically offered as an alternative. However, injectable HMAs may be burd...

Full description

Bibliographic Details
Main Authors: Audrey Delmas, Laurie Batchelder, Ira Arora, Solene Bayet, David Bruhn, Alice Eberhardt, Stephanie Philpott, Ana Maria Rodriguez-Leboeuf
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
acute myeloid leukemia
hypomethylating agents
oral treatment
patient preference
treatment preference
qualitative interview
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1160966/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1160966/full

Similar Items